InflamaCORE, LLC
 Founders:


 Dr. Robert W. Keane
Dr. Keane received his Ph.D. degree in Genetics from the University of California, Davis in 1976.  From 1976-1980 he completed a postdoctoral fellowship in Molecular Biology and Neuroscience at the Massachusetts Institute of Technology and he received a fellowship award from the Leukemia Society of America.  Dr. Keane is Professor of Physiology and Biophysics at the University of Miami, Miller School of Medicine. Over the last 30 years his research has focused on understanding the innate immune response in the central nervous system. Dr. Keane is the discoverer of inflammasomes in neurons after central nervous system injury.  Dr. Keane currently is the recipient of a fast-track STTR grant from the National Institutes of Health to develop a biologic to treated central nervous system injury and has published extensively in field of neuroinflammation. 

 Dr. Juan Pablo de Rivero Vaccari
Dr. de Rivero Vaccari received his Bachelor of Science degree in Biology in 2004 from Florida International University, where he graduated Summa Cum Laude and became a member of Phi Beta Kappa Honor Society. Dr. de Rivero Vaccari obtained his Ph.D. in 2007 for his work showing that the NLRP1 inflammasomes is a multiprotein inflammatory complex in neurons that can be therapeutically targeted to improve histopathological and functional outcomes after spinal cord injury. In 2007, he joined the laboratory of Dr. W. Dalton Dietrich at the Miami Project to Cure Paralysis as a postdoctoral fellow where Dr. de Rivero Vaccari continued his studies on innate immune responses after brain trauma. In 2010, he became a Research Assistant Professor in the Department of Neurological Surgery and the Miami Project to Cure Paralysis at the University of Miami. Currently, he works on identifying biomarkers and therapeutic targets in the innate immune response to improve outcomes after central nervous system injury and disease as well as in the spine (intervertebral disc degeneration and back pain). In addition, Dr. de Rivero Vaccari’s work has resulted in the filing of several patents with the United States Patent and Trademark Office and abroad.

 Dr. W. Dalton Dietrich
Dr. Dietrich is Scientific Director at The Miami Project to Cure Paralysis and the Kinetic Concepts Distinguished Chair in Neurosurgery at the University of Miami Miller School of Medicine.  He received his Ph.D. in Anatomy from the Medical College of Virginia in 1979 and completed a postdoctoral fellowship in the Department of Pharmacology at Washington University, St. Louis, MO, 1981.  Dr. Dietrich also serves as the Senior Associate Dean for Discovery Science at the University of Miami. His research is focused on clarifying the pathophysiology of brain and spinal cord injury with the ultimate goal of developing new therapies to protect and enhance recovery of function. Over the last 35 years, Dr. Dietrich and coworkers have studied the cellular and molecular injury mechanism underlying neurological disorders including stroke, traumatic brain and spinal cord injury. In terms of neuroprotection, he and his colleagues provided the initial preclinical data indicating that small differences in the temperature of the brain and spinal cord critically determine patterns of neuronal vulnerability. Most recently, Dr. Dietrich and colleagues have investigated the importance of abnormal inflammasome activation after brain and spinal cord injury. Dr. Dietrich and colleagues are using novel cellular treatments to promote reparative process and functional recovery after brain and SCI. He is currently the Sponsor of a first-in-man FDA approved clinical trial testing the safety of human Schwann Cell transplants after SCI. His research programs are supported by the NIH, Department of Defense, State of Florida and The Miami Project to Cure Paralysis.  He serves on several study sections and is currently Editor-In-Chief of the Journal Therapeutic Hypothermia & Temperature Management and Deputy Editor of the Journal of Neurotrauma. 

 Dr. Helen Bramlett
Dr. Bramlett is a Professor in the Department of Neurological Surgery and the Miami Project to Cure Paralysis at the University of Miami Miller School of Medicine.  She completed her BA in Psychology at the University of Texas at Austin.  She obtained her PhD degree in Behavioral Neuroscience and conducted her postdoctoral work in Neurotrauma at the University of Miami. Dr. Bramlett also serves as Director of the Undergraduate Neuroscience Program at the University of Miami.  She is a Research Health Scientist at the Miami Veterans Affairs Medical Center. Dr. Bramlett is an internationally recognized scientist with over 20 years’ experience in the field of CNS injury including the pathophysiology and treatment of traumatic brain and spinal cord injury. Her laboratory focuses on three areas of traumatic research: 1) neuroprotective strategies for traumatic injury, 2) progressive damage after trauma and 3) secondary injury mechanisms of traumatic brain injury. She is currently funded by NIH, DOD and the VA. Dr. Bramlett serves on several national review boards and is on the Editorial Board of Journal of Neurotrauma, Translational Stroke Research and BMC Neuroscience.  She is the Managing Editor of Therapeutic Hypothermia and Temperature Management.

 Advisory Board:

Steve Glover 
Mr. Glover has over 30 years of business experience in biopharmaceuticals and life sciences. Currently Mr. Glover is Co-Founder and CEO of Variant Pharmaceuticals. Before founding Variant, Mr. Glover was Co-Founder of Coherus Biosciences where he was focused on the business strategy, partnerships, product development efforts and capitalization of the company. Prior to Coherus, he was the President of Insmed Therapeutic Proteins, a biosimilar company, as well as Chief Business Officer of Insmed Incorporated.
Prior to Insmed, Mr. Glover held the position of Senior Vice President and General Manager at Andrx Laboratories and Andrx Therapeutics, both divisions of Andrx Corporation. At Andrx Mr. Glover was responsible for the strategy and operation of Andrx Labs which developed and marketed products in metabolic diseases and Men's Health and Andrx Therapeutics which was focused on the development of new controlled release products and contract manufacturing. He earlier held multiple sales, marketing and operational roles at Hoffman LaRoche, Amgen Inc. and IMS Health. 
 Mr. Glover has multifaceted experience in Fortune 100, start up and entrepreneurial environments. He has demonstrated results in start ups, large cap and turnarounds with a focus on business strategy, commercial execution, product development, business transformation and corporate development. He has over 25 life sciences transactions totaling over $10 billion in licensing and M&A activities and has raised over $200M in capital. His strategic and operational experience includes strategic planning, corporate development, operations management, product development, product marketing and sales management.
 Currently Mr. Glover serves on the Board of Directors of Variant Pharmaceuticals and InflamaCORE. Additionally Mr. Glover serves as an Executive in Residence at the University of Miami U Innovation Life Sciences Office.


Jules A. Musing

Has a 36-year career in the pharmaceutical and biotechnology industry; specifically at Johnson & Johnson and its affiliates, he has been responsible for the worldwide licensing and acquisition of pharmaceutical and biotechnology products and technologies and the establishment of strategic alliances. He was Vice President of Marketing International for the Janssen Pharmaceutical Group of Companies Worldwide from March 1982 to December 1984; President of Pitman-Moore, Inc., a U.S.-based Johnson & Johnson company from January 1985 to June 1987; Managing Director of Janssen Pharmaceutical in Portugal from July 1987 to March 1990; President of Serono, Inc. in the United States and Executive Vice President with responsibilities for North and South America from April 1990 to January 1993; Member of the board of directors of Ortho Biotech, Inc. from January 1993 to October 1999; and Managing Director of Ortho Biotech in France (a Johnson & Johnson affiliate) from October 1999 to January 2003. From January 2003 to his retirement in September 2010, Mr. Musing served as Vice President, Licensing and Acquisitions for the Pharmaceutical Group at Johnson & Johnson, where he was responsible for the worldwide licensing and acquisition of pharmaceutical and biotechnology products in all therapeutic areas. He has served as a director of Delphi Digital, Inc. since March 2012 and Chairman of the Scientific Board of Advisors for Noble Capital Financial Markets since February 2012. Currently Mr. Musing serves on the Board of Directors of Variant Pharmaceuticals and InflamaCORE.

 Dr. Nancy Stagliano
Nancy Stagliano, Ph.D. is currently Chief Executive Officer and co-founder of True North Therapeutics, a rare disease therapeutics company working in the classical complement pathway. Dr. Stagliano has an accomplished career as a biotech leader spanning all aspects of the industry, from company building, discovery research and strategy to global medical affairs and corporate communications.  Previously, Dr. Stagliano was CEO of iPierian, Inc. which applied human iPSCs to model neurodegenerative diseases. The company and its lead antibody program against Tau for the treatment of PSP and Alzheimer’s disease was acquired by BMS in April of 2014 for a total deal value of $725M.  Nancy was the CEO and co-founder of CytomX Therapeutics and a lead inventor on the patents for CytomX’s Probody platform.  In earlier roles with CytomX, she served as the COO of CytomX LLC, which launched CytomX Therapeutics as well as Cynvenio Biosystems.  Before moving to California, Nancy joined the Cambridge, Massachusetts, biotechnology industry in the late 1990s, where she had an eight-year tenure at Millennium Pharmaceuticals and consulted to several local startups.  Dr. Stagliano received her BS in Electrical Engineering and her MS in Biomedical Engineering, both from Drexel University in Philadelphia.  She obtained her PhD in Neuroscience from the University of Miami, followed by three years as an independently-funded research fellow at the Massachusetts General Hospital and Harvard Medical School, where she studied mechanisms of brain injury after stroke.

 Peter Wolfe
Mr. Wolfe has spent his career in various financial roles in the financial services, specialty finance and the pharmaceutical/healthcare industries.  Most recently Mr. Wolfe has spent his time cultivating start-up organizations in various healthcare entities, often dealing with complicated business models to develop a financial framework for success for many of these first of their kind businesses.  Mr. Wolfe has spent the last 17 years of his career in the healthcare industry with almost half of that time spent at Kos Pharmaceuticals, a publicly traded, fully-integrated specialty pharmaceutical company.  Mr. Wolfe assisted in guiding Kos to 27 straight quarters of meeting or exceeding Wall Street quarterly earnings estimates.  Finding the most cost-effective way to run a business through the design of more efficient systems is the hallmark of his career achievements.  Mr. Wolfe has his BBA from the University of Miami and his MBA from the University of Pittsburgh and is currently CFO of Variant Pharmaceuticals.